{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:34:25Z","timestamp":1761824065669,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:00:00Z","timestamp":1538179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12883-018-1165-6","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T09:46:33Z","timestamp":1538214393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Visual outcome is similar in optic neuritis patients treated with oral and i.v. high-dose methylprednisolone: a retrospective study on 56 patients"],"prefix":"10.1186","volume":"18","author":[{"given":"Magdalena","family":"Naumovska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafi","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boel","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Malmsj\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-0535","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,29]]},"reference":[{"issue":"Pt 2","key":"1165_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/brain\/110.2.405","volume":"110","author":"S Lightman","year":"1987","unstructured":"Lightman S, McDonald WI, Bird AC, Francis DA, Hoskins A, Batchelor JR, Halliday AM. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain. 1987;110(Pt 2):405\u201314.","journal-title":"Brain"},{"key":"1165_CR2","first-page":"727","volume":"65","author":"G Optic Neuritis Study","year":"2008","unstructured":"Optic Neuritis Study G. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727\u201332.","journal-title":"Arch Neurol"},{"key":"1165_CR3","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Anderson MM, Jr., Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group. N Engl J Med 1992, 326:581\u2013588.","DOI":"10.1056\/NEJM199202273260901"},{"key":"1165_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s004150070172","volume":"247","author":"F Brusaferri","year":"2000","unstructured":"Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435\u201342.","journal-title":"J Neurol"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1212\/WNL.50.1.230","volume":"50","author":"R Kapoor","year":"1998","unstructured":"Kapoor R, Miller DH, Jones SJ, Plant GT, Brusa A, Gass A, Hawkins CP, Page R, Wood NW, Compston DA, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology. 1998;50:230\u20137.","journal-title":"Neurology"},{"key":"1165_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0161-6420(88)33220-3","volume":"95","author":"TC Spoor","year":"1988","unstructured":"Spoor TC, Rockwell DL. Treatment of optic neuritis with intravenous megadose corticosteroids. A consecutive series. Ophthalmology. 1988;95:131\u20134.","journal-title":"Ophthalmology"},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0021-5155(98)00071-9","volume":"43","author":"M Wakakura","year":"1999","unstructured":"Wakakura M, Mashimo K, Oono S, Matsui Y, Tabuchi A, Kani K, Shikishima K, Kawai K, Nakao Y, Tazawa Y, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol. 1999;43:133\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","volume":"52","author":"F Sellebjerg","year":"1999","unstructured":"Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52:1479\u201384.","journal-title":"Neurology"},{"key":"1165_CR9","unstructured":"Alejandro PM, Castanon Gonzalez JA, Miranda Ruiz R, Edgar Echeverria R, Adriana Montano M: [comparative treatment of acute optic neuritis with \u201cboluses\u201d of intravenous methylprednisolone or oral prednisone]. Gac Med Mex 1994, 130:227\u2013230."},{"key":"1165_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","volume":"63","author":"SA Morrow","year":"2004","unstructured":"Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:1079\u201380.","journal-title":"Neurology"},{"key":"1165_CR11","first-page":"652","volume":"32","author":"G Groenewoud","year":"1994","unstructured":"Groenewoud G, Hundt HK, Luus HG, Muller FO, Schall R. Absolute bioavailability of a new high dose methylprednisolone tablet formulation. Int J Clin Pharmacol Ther. 1994;32:652\u20134.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1755-3768.1985.tb01585.x","volume":"63","author":"A Hedin","year":"1985","unstructured":"Hedin A, Tallstedt L. The Bostrom-Kugelberg pseudo-isochromatic plates. How efficient is the third edition? Acta Ophthalmol (Copenh). 1985;63:701\u20135.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities \"hand motion\" and \"counting fingers\" can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47:1236\u201340.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","volume":"386","author":"E Le Page","year":"2015","unstructured":"Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386:974\u201381.","journal-title":"Lancet"},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458513508835","volume":"20","author":"C Ramo-Tello","year":"2014","unstructured":"Ramo-Tello C, Grau-Lopez L, Tintore M, Rovira A, Ramio i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler. 2014;20:717\u201325.","journal-title":"Mult Scler"},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","volume":"56","author":"SM Alam","year":"1993","unstructured":"Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56:1219\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","volume":"75","author":"SA Morrow","year":"2018","unstructured":"Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, Nicolle M. Effect of treating acute optic neuritis with bioequivalent Oral vs intravenous corticosteroids a randomized clinical trial. Jama Neurol. 2018;75:690\u20136.","journal-title":"Jama Neurol"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","volume":"111","author":"RW Beck","year":"1993","unstructured":"Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773\u20135.","journal-title":"Arch Ophthalmol"},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","volume":"62","author":"PW O'Connor","year":"2004","unstructured":"O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA. Natalizumab multiple sclerosis trial G: randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62:2038\u201343.","journal-title":"Neurology"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/WNO.0b013e31828ea2fc","volume":"33","author":"X An","year":"2013","unstructured":"An X, Kezuka T, Usui Y, Matsunaga Y, Matsuda R, Yamakawa N, Goto H. Suppression of experimental autoimmune optic neuritis by the novel agent fingolimod. J Neuroophthalmol. 2013;33:143\u20138.","journal-title":"J Neuroophthalmol"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/jnnp-2014-308185","volume":"86","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, Balcer LJ, Markowitz CE, Vartanian T, Morrow M, et al. Re-evaluating the treatment of acute optic neuritis. J Neurol Neurosurg Psychiatry. 2015;86:799\u2013808.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","volume":"101","author":"RW Beck","year":"1994","unstructured":"Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology. 1994;101:1771\u20138.","journal-title":"Ophthalmology"},{"key":"1165_CR23","doi-asserted-by":"crossref","unstructured":"Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015:CD001430.","DOI":"10.1002\/14651858.CD001430.pub4"},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","volume":"115","author":"Optic Neuritis Study G","year":"2008","unstructured":"Optic Neuritis Study G. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008;115:1079\u201382 e1075.","journal-title":"Ophthalmology"},{"key":"1165_CR25","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0161-6420(95)30839-1","volume":"102","author":"RW Beck","year":"1995","unstructured":"Beck RW, Trobe JD. What we have learned from the optic neuritis treatment trial. Ophthalmology. 1995;102:1504\u20138.","journal-title":"Ophthalmology"},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","volume":"73","author":"V Martinelli","year":"2009","unstructured":"Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology. 2009;73:1842\u20138.","journal-title":"Neurology"},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.41.8.1219","volume":"41","author":"F Barkhof","year":"1991","unstructured":"Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991;41:1219\u201322.","journal-title":"Neurology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1165-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-018-1165-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1165-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:13:12Z","timestamp":1662163992000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-018-1165-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1186\/s12883-018-1165-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2018,9,29]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data access was legally approved by the Ethics Committee (Regionala etikpr\u00f6vningsn\u00e4mnden i Lund) at Lund University, Sweden. The research adhered to the tenets of the Declaration of Helsinki as amended in 2008. The study is based on anonymized data and never involved patients directly. Individual patients cannot be identified. Consent to participate was not needed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"160"}}